Evidence map›Paper›PMID 37315262›Full record

ReviewJCO precision oncology2023

Venetoclax and Azacitidine in the Treatment of

Julie Ma, Kenji Morimoto, Michael A Pulsipher, Chintan Parekh

Open access · hybridAbstract readReviewCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Review in JCO precision oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
2.0field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 4 institutions in 1 country.

Julie MaCancer and Blood Disease Institute, Children's Hospital Los Angeles, Los Angeles, CA.ORCID 0000-0003-4393-2927
Kenji MorimotoDepartment of Pediatrics, Kaiser Permanente Fontana Medical Center, Fontana, CA.
Michael A PulsipherDivision of Pediatric Hematology and Oncology, Intermountain Primary Children's Hospital, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT.ORCID 0000-0003-3030-8420
Chintan ParekhCancer and Blood Disease Institute, Children's Hospital Los Angeles, Los Angeles, CA.
Children's Hospital of Los Angeles · USKaiser Permanente Fontana Medical Center · USPrimary Children's Hospital · USUniversity of Southern California · US

Funding

Randomized study of low versus moderate dose busulfan in transplant for severe combined immunodeficiencyU01AI126612 · NIAID · CHILDREN'S HOSPITAL OF LOS ANGELES · PI KEAN, LESLIE S, PULSIPHER, MICHAEL A · 2017 to 2023
$8.5M
Unrelated Donor BMT vs. Immune Suppression for Newly Diagnosed Severe Aplastic Anemia in Children and Young Adults: BMT CTN Core Center Renewal for the Pediatric Blood and Marrow Transplant ConsortiumUG1HL069254 · NHLBI · CHILDREN'S HOSPITAL OF LOS ANGELES · PI KEAN, LESLIE S · 2017 to 2023
$1.3M
NHLBI NIH HHS UG1 HL069254NIAID NIH HHS U01 AI126612
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Fanconi AnemiaLeukemiaAzacitidineBridged Bicyclo Compounds, HeterocyclicHumansNuclear ProteinsSulfonamidesAzacitidineBridged Bicyclo Compounds, HeterocyclicNuclear ProteinsSulfonamidesvenetoclax

Identifiers

PMID37315262
PMCPMC10309544
OpenAlexW4380591255

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.